MedTrace Logo

TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer

NCT01282151 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2015-07-14

No results posted yet for this study

Summary

This study is:

* A multicenter, prospective, randomized, phase 3 trial.
* To prove non-inferiority of Taxotere/Cisplatin compared to Pemetrexed/Cisplatin as a front line treatment of patients with non-squamous cell lung cancer.
* 276 patients will be recruited.

Conditions

  • Carcinoma, Non Small Cell Lung

Interventions

DRUG

Taxotere

Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks

DRUG

Pemetrexed

Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Chonnam National University Hospital

    lead OTHER

Principal Investigators

  • Young-Chul Kim, MD, PhD · Chonnam National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-12-31
Completion
2014-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01282151 on ClinicalTrials.gov